Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Evolving strategies to prevent HBV recurrence.

Bruno Roche1, Didier Samuel

  • 1Centre Hépatobiliaire, Hôpital Paul Brousse, Villejuif, France.

Liver Transplantation : Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society
|September 24, 2004
PubMed
Summary

Hepatitis B immune globulin (HBIG) and antiviral treatments like lamivudine (LAM) reduce hepatitis B virus (HBV) recurrence after liver transplants. Combination therapy is highly effective, but optimal protocols require further study.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Liver Transplantation for HBV-Related Disease in France: NUC Type Before LT Is Associated With Patient Survival.

Liver international : official journal of the International Association for the Study of the Liver·2026
Same author

Real-world effectiveness and safety of bulevirtide monotherapy for up to 96 weeks in patients with HDV-related cirrhosis.

Journal of hepatology·2025
Same author

Treatment with bulevirtide in HIV-infected patients with chronic hepatitis D: ANRS HD EP01 BuleDelta and compassionate cohort.

JHEP reports : innovation in hepatology·2024
Same author

HLA-DQ Diversity Is Associated With Humoral Response to Vaccines in Patients Awaiting or After Liver Transplantation.

Gastroenterology·2024
Same author

Correction: Balaphas et al. Cell Therapy for Anal Sphincter Incontinence: Where Do We Stand? <i>Cells</i> 2021, <i>10</i>, 2086.

Cells·2023
Same author

Robotic mesh rectopexy for rectal prolapse: The Geneva technique-A video vignette.

Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland·2023

Area of Science:

  • Hepatology
  • Transplantation Immunology
  • Virology

Background:

  • Hepatitis B virus (HBV) recurrence post-liver transplant poses significant risks.
  • Hepatitis B immune globulin (HBIG) prophylaxis is standard but has limitations, especially in high-risk patients.
  • Antiviral agents like lamivudine (LAM) show promise in pre- and post-transplant management.

Purpose of the Study:

  • To review the efficacy of HBIG and antiviral prophylaxis in preventing HBV recurrence after orthotopic liver transplantation (OLT).
  • To evaluate the role of lamivudine (LAM) and adefovir dipivoxil (ADV) in managing HBV infection around OLT.
  • To identify optimal prophylaxis strategies in the current treatment era.

Main Methods:

  • Review of existing literature on HBIG and antiviral prophylaxis for HBV recurrence post-OLT.

Related Experiment Videos

  • Analysis of studies evaluating lamivudine (LAM) and adefovir dipivoxil (ADV) efficacy and resistance.
  • Synthesis of data on combination prophylaxis regimens.

    • Main Results:

    • Long-term HBIG prophylaxis reduces HBV recurrence and improves survival.
    • Pre-OLT LAM can suppress HBV replication; ADV may be rescue therapy.
    • Combination prophylaxis with LAM and HBIG achieves 90-100% prevention of HBV recurrence.

    Conclusions:

    • Combination prophylaxis with LAM and HBIG is highly effective in preventing HBV recurrence.
    • Optimal HBIG protocols and the role of ADV/LAM as first-line post-transplant therapy need further investigation.
    • Future research should explore reduced HBIG doses and alternative strategies like vaccination.